Evidence map›Paper›PMID 8254015›Full record

ArticleThe Journal of clinical investigation1993

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.

R Balena, B C Toolan, M Shea, A Markatos, E R Myers, S C Lee, E E Opas, J G Seedor, H Klein, D Frankenfield

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 399 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. An overview of de novo bone generation in animal models.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021
    Review
  8. Article
  9. Perspectives on the non-invasive evaluation of femoral strength in the assessment of hip fracture risk.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Possible antiosteoporotic mechanism of Cicer arietinum extract in ovariectomized rats.International journal of clinical and experimental pathology · 2015
    Article
  19. Article
  20. Bisphosphonates and bone quality.BoneKEy reports · 2014
    Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

R BalenaMerck Research Laboratories, West Point, Pennsylvania 19486.
B C Toolan
M Shea
A Markatos
E R Myers
S C Lee
E E Opas
J G Seedor
H Klein
D Frankenfield
United States Military Academy · USBeth Israel Deaconess Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study examined the effect of 2 yr of treatment with the aminobisphosphonate alendronate (ALN) (0.05 or 0.25 mg/kg i.v. ALN every 2 wk) on estrogen deficiency bone loss and bone strength changes in ovariectomized (OVX) baboons (n = 7 per group) and the ALN mode of action at the tissue level. Biochemical markers of bone turnover increased in OVX animals and were maintained by ALN treatment at non-OVX levels (low dose) or below (high dose). 2 yr of treatment produced no cumulative effects on bone turnover markers. Histomorphometry showed a marked increase in cancellous bone remodeling in OVX animals. Activation frequency increased from 0.48 to 0.86 per yr (L5 vertebra), and the osteoid surfaces from 9 to 13.5% (P < 0.05). No changes were observed in eroded and osteoclast surfaces. ALN treatment decreased activation frequency and indices of bone formation to control levels (low dose) or below (high dose), did not change indices of mineralization, and increased bone mineral density (BMD) in the lumbar vertebrae (L2-L4) by 15% at 0.25 mg/kg (P < 0.05), relative to vehicle-treated animals. The mean strength of cancellous bone (L4) increased by 44% (low ALN dose) and 100% (high dose), compared with vehicle. The strength of individual bones correlated with the square of the L2-L4 BMD (r = 0.91, P < 0.0034). In conclusion, ALN treatment reversed the effects of ovariectomy on cancellous bone turnover and increased bone mass and bone strength in baboons.

Indexed as

OvariectomyAcid PhosphataseAlendronateAlkaline PhosphataseAnimalsBiomarkersBone and BonesCalcification, PhysiologicCalcitoninCalciumCreatinineDiphosphonatesDose-Response Relationship, DrugFemalePapioParathyroid HormoneAcid PhosphataseAlendronateAlkaline PhosphataseBiomarkersCalcitoninCalciumCreatinineDiphosphonatesParathyroid HormonePhosphates

Identifiers

PMID8254015
PMCPMC288453
OpenAlexW2022641698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.